QC Kinetix Medical Management Team Member Publishes Findings on the Restorative Potential of Donor-Based Therapies

CHARLOTTE, N.C., Sept. 16, 2025 /PRNewswire/ -- Can recent developments in regenerative medicine help us heal faster, reduce chronic pain, and improve our quality of life? The answer is yes, according to a newly published review article by QC Kinetix Medical Management Team Member Dr. Theodore Sand, PhD. The title of the article authored by Dr. Sand is "A survey of the composition, safety, efficacy and regulation of non-autologous biologic treatments in human musculoskeletal pathologies".

Dr. Sand, a biotechnology and regenerative medicine consultant with more than two decades of experience, reviewed in the publication a broad spectrum of clinical studies assessing the therapeutic potential of donor tissues and cells. His review suggests that there are a wide range of therapeutic options that might be used in regenerative medicine to augment the body's natural healing power, with clinical studies showing how these therapies address injuries and pain associated with different musculoskeletal pathologies.

"Regenerative medicine takes aim at repairing the root cause of damage," said Dr. Sand. "For patients, that focus means there is a potential for faster recovery, more durable relief, and the chance to improve one's quality of life once thought to be lost."

Breaking Down NABs: Donor-Based Therapies Providing New Options for Regenerative Medicine
Non-autologous biologics (NABs) are therapies developed from donated cells and tissues rather than using the patient's own tissues like blood or bone marrow. The review by Dr. Sand summarizes outcomes from recent clinical studies with a variety of NABs that generally have shown beneficial outcomes in treating musculoskeletal conditions such as:

• Joint pain
• Sports injuries
• Degenerative tissue disorders (e.g., soft tissue pain)

The U.S. Food and Drug Administration (USFDA) regulates NAB products under both the Food, Drug and Cosmetic Act and the Public Health Service Act, requiring a rigorous approval process to ensure safety and effectiveness before these treatments can be marketed. Currently, none of the non-wound applications of NABs have been approved.

Are NABs Safe? What the Science Really Says
Dr. Sand's review highlights that most NABs have demonstrated an acceptable safety profile when applied appropriately, with no serious adverse events associated with the therapeutic product reported in multiple studies. The most common side effects were minor, temporary soreness or inflammation.

"Safety is paramount," Dr. Sand added. "All donor tissues must undergo strict screening for the presence of infectious bacteria and harmful viruses and are processed to meet USFDA standards for sterility and safety. While NAB therapies are under active investigation in approved clinical studies in various clinical settings, larger studies are essential to confirm their long-term efficacy and safety across diverse patient populations. Physicians wishing to use NABs need to consider the regulatory status of the products being offered—most products outside of wound care aren't approved by the USFDA and should be used with patients only in an Institutional Review Board-approved clinical study."

The Future of Healing: What Dr. Sand's Review Reveals
According to Dr. Sand's analysis, NABs could find expanding applications in treating:

• Wounds and burns
• Degenerative changes in soft tissues
• Joint pain

While regenerative medicine is not a cure for aging, it can help patients manage the pain and loss of quality of life that often comes with aging. NAB therapies have the potential to aid in restoring mobility, reducing chronic discomfort, and enabling people to live healthier lives as they age.

"By leveraging donor tissues and cells, we're seeing the development of therapies that have a potential to repair tissue pathologies, while also reducing pain," concluded Dr. Sand. "As NAB products gain regulatory approval, patients will have access to more options for treatment, with a potential to reduce dependence on opioid pain medication and ultimately offer people an opportunity to return to a life with reduced or no chronic pain."

For more information about QC Kinetix, visit https://qckinetix.com.

About QC Kinetix
Founded in 2017 and based in Charlotte, North Carolina, QC Kinetix is the largest regenerative medicine franchise in North America, recognized by the Inc. 5000 as one of America's fastest-growing private companies. The brand delivers non-surgical, biologic-based treatments to help patients address joint pain, injuries, and musculoskeletal conditions by stimulating the body's natural healing processes. QC Kinetix began franchising in 2020 and now operates more than 100 clinics across the U.S., with plans for 350 nationwide.

View original content to download multimedia:https://www.prnewswire.com/news-releases/unlocking-the-bodys-natural-healing-power-new-publication-reveals-breakthroughs-in-regenerative-medicine-302557772.html

SOURCE QC Kinetix